U.S. Central Nervous System Biomarkers Market Size, Share & Forecast 2026–2032

ID: MR-11391 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Central Nervous System Biomarkers Market
  • ✓Market Size 2024: USD 1.42 billion
  • ✓Market Size 2032: USD 2.61 billion
  • ✓CAGR: 7.9%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Analyzer Footprint Decides Winners: Fujirebio's Lumipulse plasma p-tau217 assay received FDA clearance in 2025 and runs on analyzers already installed in hospital core laboratories. Analyzer footprint, not biomarker novelty, will decide which vendors capture reimbursement-driven volume through 2032.
FINDING 02
Blood Tests Displace PET: Consensus holds that PET and spinal fluid testing remain the diagnostic standard. Plasma biomarkers will instead displace a growing share of amyloid PET referrals in community neurology, shifting volume toward Labcorp and Quest Diagnostics rather than imaging centers.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure Analyzer Placements Early: Diagnostics manufacturers and reference laboratories should secure hospital analyzer placements with at least three large health systems before the end of 2026, since installed-base contracts will lock in reagent revenue through 2032.

CNS Biomarkers in the U.S.: Competitive Overview

The U.S. CNS biomarkers market is concentrated at the instrument level and fragmented at the test level. Roche Diagnostics, Fujirebio, Siemens Healthineers and Beckman Coulter hold most installed immunoassay analyzers in hospital laboratories, while Quanterix and Alamar Biosciences compete on high-sensitivity single-molecule and proteomic platforms. Few independent developers own both the analyzer and the reagent economics, and reference laboratories Labcorp and Quest Diagnostics control test distribution and billing access.

International manufacturers dominate instrument supply, whereas domestic players dominate laboratory services and direct-to-clinician channels. C2N Diagnostics, based in St. Louis, competes through its PrecivityAD2 mass spectrometry test offered as a laboratory-developed test, which bypasses some analyzer lock-in. Competitive advantage in this country depends on FDA clearance status, CMS reimbursement coding, installed analyzer footprint, and integration with electronic health record ordering workflows.

Demand Drivers Shaping CNS Biomarkers in the U.S.

Aging demographics and rising Alzheimer's diagnosis rates are the largest volume driver. Medicare coverage of anti-amyloid monoclonal antibodies, lecanemab and donanemab, requires confirmed amyloid pathology before treatment, which expands testing demand in neurology clinics. Eli Lilly and Eisai benefit indirectly, because each prescription pulls a biomarker confirmation test that diagnostics vendors capture.

Expansion of blood-based testing into primary care is the second driver. Federal reimbursement for plasma-based amyloid tests favors vendors with national collection networks, so Labcorp and Quest Diagnostics gain share against smaller specialty laboratories. Third, electronic health record integration of ordering and result workflows rewards platforms that connect directly to Epic and Oracle Health, giving large immunoassay manufacturers a structural advantage.

Competitive Restraints and Market Challenges

Price pressure is intensifying as multiple plasma assays enter the market. Medicare Clinical Laboratory Fee Schedule rates limit the premium that new entrants can command, and payers increasingly demand head-to-head performance data before granting coverage. Smaller developers without installed analyzer bases face margin compression, which is driving consolidation through acquisitions by larger diagnostics groups.

The FDA's 2024 final rule on laboratory-developed tests, whose implementation a federal court blocked in 2025, created uncertainty that raised compliance planning costs for single-site developers. Specialized neuropathologists and clinical chemists remain scarce, and many community hospitals lack the mass spectrometry capacity needed for confirmatory testing. Infrastructure gaps in rural counties further restrict competitive reach beyond academic medical centers.

Growth Opportunities for Market Players

Primary care screening and pre-symptomatic risk stratification represent the largest untapped segment. Vendors building plasma assays suited to primary care collection target community clinics that currently refer patients to specialists for confirmation. Partnerships with retail health providers and telehealth platforms offer distribution routes that bypass traditional hospital procurement cycles.

Parkinson's disease, frontotemporal dementia, and multiple sclerosis present adjacent opportunities as alpha-synuclein seed amplification assays and neurofilament light chain tests mature. Quanterix and Alamar Biosciences are positioned to supply multiplex panels to pharmaceutical sponsors running clinical trials, where biomarker enrichment determines enrollment. Companion diagnostic agreements with drug sponsors generate recurring revenue that stands apart from reimbursement-dependent testing.

Market at a Glance

MetricDetails
Market Size 2024USD 1.42 billion
Market Size 2032USD 2.61 billion
Growth Rate (CAGR)7.9%
Most Critical Decision FactorInstalled analyzer footprint and reimbursement coding access
Largest RegionNortheast U.S.
Competitive StructureOligopolistic instruments, fragmented testing services

Leading Market Participants

  • Roche Diagnostics
  • Fujirebio
  • Quanterix
  • C2N Diagnostics
  • Labcorp
  • Quest Diagnostics
  • Siemens Healthineers
  • Beckman Coulter
  • Bio-Rad Laboratories
  • Alamar Biosciences

Regulatory and Policy Environment

The FDA regulates CNS biomarker assays through 510(k), De Novo, and Breakthrough Devices Program pathways, and clearance status directly determines which vendors can sell into hospital laboratories without restriction. The Clinical Laboratory Improvement Amendments of 1988, administered by CMS, govern laboratory certification, while the Protecting Access to Medicare Act framework sets Clinical Laboratory Fee Schedule rates that Congress has repeatedly delayed. These rules favor established manufacturers with regulatory affairs teams and penalize small developers.

CMS's 2022 national coverage determination for anti-amyloid antibodies imposed a registry requirement under coverage with evidence development, which shapes how biomarker confirmation data is collected and reported. Medicare reimbursement for amyloid testing depends on documented clinical pathways, so vendors that supply payer evidence packages secure preferred access. Competitive positioning therefore rests on regulatory strategy as much as analytical performance.

Competitive Outlook for CNS Biomarkers in the U.S.

By 2032, instrument supply will remain concentrated among four or five global diagnostics manufacturers, while test volume will shift toward reference laboratories with national collection networks. Plasma assays will become the default first-line test in neurology and primary care, compressing the share held by PET imaging and cerebrospinal fluid testing. Vendors that secure hospital analyzer placements early will hold the strongest reagent revenue positions.

Consolidation is the most probable structural change, as smaller developers without installed bases are acquired by large diagnostics groups seeking neurology menus. Domestic companies such as C2N Diagnostics and Quanterix will compete on specialized platforms and pharmaceutical partnerships rather than hospital instrument volume. Competitive success will increasingly depend on payer evidence, regulatory agility, and integration into electronic health record ordering systems.

Frequently Asked Questions

Roche Diagnostics and Fujirebio lead in immunoassay instrument placements, while Labcorp and Quest Diagnostics lead in test volume. Quanterix and C2N Diagnostics compete in advanced platform and proteomic testing.
Instrument supply is concentrated among four or five global diagnostics manufacturers. Test services are fragmented across national reference laboratories and regional specialty laboratories.
FDA clearance status, CMS reimbursement coding, and installed analyzer footprint in hospital laboratories are the primary determinants. Integration with electronic health record ordering workflows is an increasingly important fourth factor.
Domestic firms win in laboratory services and direct clinician channels, while multinationals win in hospital instrument placements. C2N Diagnostics and Quanterix show that U.S.-based developers can scale in specialized niches.
New entrants should prioritize FDA submission strategy and payer evidence packages before pursuing scale. Partnering with an established reference laboratory provides immediate national collection access.

Market Segmentation

By Product Type
  • Immunoassay Analyzers and Reagents
  • Mass Spectrometry Platforms
  • PET Imaging Tracers
  • Genetic and Molecular Assays
By Disease Area
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Frontotemporal Dementia
By End User
  • Hospitals
  • Reference Laboratories
  • Academic Medical Centers
  • Pharmaceutical Sponsors

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 CNS Biomarkers in the U.S. - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Product Type Insights
4.1 Immunoassay Analyzers and Reagents
4.2 Mass Spectrometry Platforms
4.3 PET Imaging Tracers
4.4 Genetic and Molecular Assays
4.5 Others
Chapter 05 Disease Area Insights
5.1 Alzheimer's Disease
5.2 Parkinson's Disease
5.3 Multiple Sclerosis
5.4 Frontotemporal Dementia
5.5 Others
Chapter 06 End User Insights
6.1 Hospitals
6.2 Reference Laboratories
6.3 Academic Medical Centers
6.4 Pharmaceutical Sponsors
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Roche Diagnostics
7.2.2 Fujirebio
7.2.3 Quanterix
7.2.4 C2N Diagnostics
7.2.5 Labcorp
7.2.6 Quest Diagnostics
7.2.7 Siemens Healthineers
7.2.8 Beckman Coulter
7.2.9 Bio-Rad Laboratories
7.2.10 Alamar Biosciences
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.